Phase II study of sunitinib malate in patients with recurrent high-grade glioma

By Neyns B.   Sadones J.   Chaskis C.   Dujardin M.   Everaert H.   Lv S.   Duerinck J.   Tynninen O.   Nupponen N.   Michotte A.   Greve J.  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 491-501

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma

By Tang P.   Roldan G.   Brasher P.M.A   Fulton D.   Roa W.   Murtha A.   Cairncross J.G.   Forsyth P.A.  

Journal of Neuro-Oncology, Vol. 78, Iss. 3, 2006-07 ,pp. : 311-316

Springer Publishing Company

Access to resources Recommend Favorite

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study

By Fabi Alessandra   Metro Giulio   Vidiri Antonello   Lanzetta Gaetano   Carosi Mariantonia   Telera Stefano   Maschio Marta   Russillo Michelangelo   Sperduti Isabella   Carapella Carmine   Cognetti Francesco   Pace Andrea  

Journal of Neuro-Oncology, Vol. 100, Iss. 2, 2010-11 ,pp. : 209-215

Springer Publishing Company

Access to resources Recommend Favorite

Carboplatin and bevacizumab for recurrent malignant glioma

By        

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 1082-1086

Spandidos Publications

Access to resources Recommend Favorite

131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma: Phase I and II Study

By Riva Pietro   Franceschi Giancarlo   Frattarelli Massimo   Riva Nada   Guiducci Graziano   Cremonini Anna Maria   Giuliani Graziano   Casi Michela   Gentile Rossella   Jekunen Annti A.   Kairemo Kalevi J. A.  

Acta Oncologica, Vol. 38, Iss. 3, 1999-05 ,pp. : 351-359

Informa Healthcare

Access to resources Recommend Favorite